Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ingevity (NGVT) Research & Development (2016 - 2025)

Ingevity (NGVT) has disclosed Research & Development for 10 consecutive years, with $5.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development fell 9.23% to $5.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $28.4 million, a 4.03% increase, with the full-year FY2025 number at $28.4 million, up 15.92% from a year prior.
  • Research & Development was $5.9 million for Q4 2025 at Ingevity, down from $7.0 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $8.8 million in Q1 2023 to a low of $800000.0 in Q4 2023.
  • A 5-year average of $6.9 million and a median of $7.1 million in 2021 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: plummeted 88.89% in 2023, then soared 712.5% in 2024.
  • Ingevity's Research & Development stood at $7.0 million in 2021, then grew by 2.86% to $7.2 million in 2022, then tumbled by 88.89% to $800000.0 in 2023, then skyrocketed by 712.5% to $6.5 million in 2024, then decreased by 9.23% to $5.9 million in 2025.
  • Per Business Quant, the three most recent readings for NGVT's Research & Development are $5.9 million (Q4 2025), $7.0 million (Q3 2025), and $7.8 million (Q2 2025).